Trying NMN and EGA® to improve exercise ability in healthy older adults
Official title: Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults
Run by Concordia University Chicago · NCT07144527 · Data updated 2026-11-12
This study will test whether the proprietary EGA® supplement or conventional NMN helps improve exercise endurance in healthy people aged 60–80.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 60 Years to 80 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Concordia University Chicago Academic / other |
| Locations | 1 site (Beverly Hills, California) |
| Status | Recruiting |
| Started | February 21, 2026 |
| Main results expected | December 30, 2026 |
| Study ends | January 1, 2027 |
| Registry record updated | October 7, 2026 |
| Trial ID | NCT07144527 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Healthy adults aged 60–80 who have medical clearance for moderate-to-vigorous exercise, normal recent cardiac testing, MoCA ≥26, and the ability to perform structured cycling are ideal candidates.
✕Probably not a fit
People with uncontrolled medical conditions, significant cardiac abnormalities on recent testing, cognitive impairment (MoCA <26), or who cannot perform moderate-to-vigorous cycling are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, double-blind, placebo-controlled, two-arm crossover trial compares a proprietary NAD+-modulating formulation (EGA®) with conventional nicotinamide mononucleotide (NMN) supplementation in healthy older adults. Participants will self-administer twice-daily oral doses that provide 1000 mg NMN per day, with the EGA® arm including two additional endogenous metabolomic compounds. The primary outcome is time to fatigue on constant work rate cycle ergometry, with secondary outcomes including VO₂peak, lactate threshold, anaerobic work capacity, critical power, and circulating NAD+ metabolites. The trial is designed to measure short-term physiological effects and safety under controlled exercise testing and will inform whether the proprietary combination offers added benefit over standard NMN.
Why it matters
Potential benefit: If successful, the interventions could increase submaximal exercise tolerance and improve biomarkers related to aging in older adults.
How similar studies have gone: Prior human studies of NMN and other NAD+ precursors have shown modest and sometimes mixed improvements in metabolic markers and physical function, while EGA®'s specific proprietary combination has limited published clinical data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 60 to 80 years, of any sex * Written clearance from primary care physician confirming medical fitness to participate in an exercise-based clinical study * Normal or near-normal cardiovascular function to safely engage in moderate to vigorous exercise, demonstrated by either: stress echocardiogram or coronary CT angiogram within the past 12 months showing normal left ventricular function, no significant valvular heart disease, no ischemic changes, and no other clinically significant abnormalities, plus confirmation that no new cardiovascular symptoms (e.g., chest pain, dyspnea, syncope) or changes in health status have occurred since testing * Montreal Cognitive Assessment (MoCA) score of 26 or higher * Free from acute or uncontrolled chronic medical conditions that would pose a risk or interfere with study participation * Physically capable of engaging in structured exercise involving moderate to vigorous intensity stationary cycling * Successful completion of a graded exercise test (e.g., stationary bike) without significant adverse events or contraindications * Ability to attend at least four in-person laboratory visits in Beverly Hills, California * Non-smoker for at least 12 months * Able to provide informed consent and comply with study procedures * Willing to refrain from initiating new exercise, dietary supplement, or medication regimens during the study Exclusion Criteria: * Severe cardiovascular disease (e.g., recent myocardial infarction \<6 months, unstable angina, uncontrolled hypertension \>160/100 mmHg) * Severe respiratory conditions (e.g., advanced COPD or other conditions preventing exercise participation) * Significant neurological impairments that hinder comprehension of instructions or participation in exercise * Terminal illness or conditions limiting life expectancy or ability to complete the study * Severe cognitive impairment preventing informed consent, protocol adherence, or comprehension of interventions * Significant orthopedic limitations or injuries that prevent safe exercise participation * Use of NMN, NR, or other NAD+-altering supplements within the past 14 weeks * Anticipated or current alcohol consumption \>2 drinks per week, or unwillingness to abstain from alcohol during the study * Current substance abuse affecting study participation or adherence * Other acute or chronic health conditions judged by the investigators to pose risk or interfere with study objectives * Non-compliance with study requirements, withdrawal of informed consent, or unforeseen circumstances compromising completion * Any condition which, in the opinion of the investigator, would interfere with study participation or interpretation of results
Where it's running
-
Medical Office of Dr. Robert Huizenga MD
Beverly Hills, California, United States Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Longevity Metrics AI/ML Development Study
Researchers are testing AI models that score health screening tests and predict outcomes like life expectancy for adults, using ongoing follow-up data.
-
Acupoint Stimulation and Exercise for Pre-frail Older Adults in Taiwan
This study tests whether combining exercise with daytime and sleep-improving acupoint stimulation helps pre-frail adults 50 and older in Taiwan feel less frail and sleep better.
-
Centenarian cohort in Navarre to study aging and longevity
This study tests what factors help centenarians in Navarre stay healthier as they age and what might explain their exceptional longevity.
-
Health Ahead: Comparing AI vs. Humans for Preventive Health Screening
This study tests AI-assisted screening interpretation against human-only reads to see if automated screening can match or improve current practice for adults, especially in underserved areas.
-
How environment and biology together predict health, aging, and death
Researchers are following adults to see how living conditions and biology together relate to aging and life expectancy, by linking personal health data with environmental and social information over time.
-
100-Year Human Aging and Longevity Tracking Program
This project will follow adults over their lifetimes to see if repeated health tests can predict lifespan, causes of death, serious disease, and loss of function.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.